JP2018522850A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018522850A5 JP2018522850A5 JP2017565142A JP2017565142A JP2018522850A5 JP 2018522850 A5 JP2018522850 A5 JP 2018522850A5 JP 2017565142 A JP2017565142 A JP 2017565142A JP 2017565142 A JP2017565142 A JP 2017565142A JP 2018522850 A5 JP2018522850 A5 JP 2018522850A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- antagonist
- seq
- administered
- chain variable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims description 92
- 239000003814 drug Substances 0.000 claims description 74
- 229940123751 PD-L1 antagonist Drugs 0.000 claims description 62
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 58
- 206010028980 Neoplasm Diseases 0.000 claims description 41
- 201000011510 cancer Diseases 0.000 claims description 36
- 102000008096 B7-H1 Antigen Human genes 0.000 claims description 27
- 108010074708 B7-H1 Antigen Proteins 0.000 claims description 27
- 229940124674 VEGF-R inhibitor Drugs 0.000 claims description 27
- 239000003795 chemical substances by application Substances 0.000 claims description 19
- 229940079593 drug Drugs 0.000 claims description 17
- 208000006265 Renal cell carcinoma Diseases 0.000 claims description 14
- 239000005557 antagonist Substances 0.000 claims description 13
- RITAVMQDGBJQJZ-FMIVXFBMSA-N axitinib Chemical group CNC(=O)C1=CC=CC=C1SC1=CC=C(C(\C=C\C=2N=CC=CC=2)=NN2)C2=C1 RITAVMQDGBJQJZ-FMIVXFBMSA-N 0.000 claims description 12
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims description 11
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 claims description 11
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims description 11
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 claims description 11
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 9
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 9
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 9
- 238000003364 immunohistochemistry Methods 0.000 claims description 8
- 229960003005 axitinib Drugs 0.000 claims description 7
- 230000003442 weekly effect Effects 0.000 claims description 7
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims description 6
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims description 6
- 208000017604 Hodgkin disease Diseases 0.000 claims description 6
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims description 6
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims description 6
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims description 6
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims description 6
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims description 6
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 6
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 6
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims description 6
- 206010041067 Small cell lung cancer Diseases 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 6
- 208000000587 small cell lung carcinoma Diseases 0.000 claims description 6
- 238000003556 assay Methods 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 5
- 102000004169 proteins and genes Human genes 0.000 claims description 5
- 108090000623 proteins and genes Proteins 0.000 claims description 5
- 238000012360 testing method Methods 0.000 claims description 5
- 210000004027 cell Anatomy 0.000 claims description 4
- 201000001441 melanoma Diseases 0.000 claims description 4
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 3
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims description 3
- 206010005003 Bladder cancer Diseases 0.000 claims description 3
- 206010006187 Breast cancer Diseases 0.000 claims description 3
- 208000026310 Breast neoplasm Diseases 0.000 claims description 3
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 3
- 208000034578 Multiple myelomas Diseases 0.000 claims description 3
- 206010033128 Ovarian cancer Diseases 0.000 claims description 3
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 3
- 206010060862 Prostate cancer Diseases 0.000 claims description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 3
- 206010038389 Renal cancer Diseases 0.000 claims description 3
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 claims description 3
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 3
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 claims description 3
- 201000003444 follicular lymphoma Diseases 0.000 claims description 3
- 201000010982 kidney cancer Diseases 0.000 claims description 3
- 201000005243 lung squamous cell carcinoma Diseases 0.000 claims description 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 3
- 208000025113 myeloid leukemia Diseases 0.000 claims description 3
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 3
- 201000002528 pancreatic cancer Diseases 0.000 claims description 3
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 3
- 206010041823 squamous cell carcinoma Diseases 0.000 claims description 3
- 208000022679 triple-negative breast carcinoma Diseases 0.000 claims description 3
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 3
- 101001056180 Homo sapiens Induced myeloid leukemia cell differentiation protein Mcl-1 Proteins 0.000 claims description 2
- 102100026539 Induced myeloid leukemia cell differentiation protein Mcl-1 Human genes 0.000 claims description 2
- 208000015347 renal cell adenocarcinoma Diseases 0.000 claims description 2
- 239000003446 ligand Substances 0.000 claims 2
- 229940121647 egfr inhibitor Drugs 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 29
- 238000011127 radiochemotherapy Methods 0.000 description 10
- 229940123494 CD20 antagonist Drugs 0.000 description 9
- 238000002648 combination therapy Methods 0.000 description 9
- YTKUWDBFDASYHO-UHFFFAOYSA-N bendamustine Chemical compound ClCCN(CCCl)C1=CC=C2N(C)C(CCCC(O)=O)=NC2=C1 YTKUWDBFDASYHO-UHFFFAOYSA-N 0.000 description 6
- 229960002707 bendamustine Drugs 0.000 description 6
- 238000011282 treatment Methods 0.000 description 6
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 description 5
- 229960002756 azacitidine Drugs 0.000 description 5
- 238000002721 intensity-modulated radiation therapy Methods 0.000 description 4
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 3
- 208000020990 adrenal cortex carcinoma Diseases 0.000 description 3
- 208000007128 adrenocortical carcinoma Diseases 0.000 description 3
- 229950002916 avelumab Drugs 0.000 description 3
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 3
- 229960004316 cisplatin Drugs 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 206010044412 transitional cell carcinoma Diseases 0.000 description 3
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 230000002055 immunohistochemical effect Effects 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 208000019465 refractory cytopenia of childhood Diseases 0.000 description 2
- 229960004641 rituximab Drugs 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 208000023747 urothelial carcinoma Diseases 0.000 description 2
- 229920002554 vinyl polymer Polymers 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000002030 Merkel cell carcinoma Diseases 0.000 description 1
- 206010029266 Neuroendocrine carcinoma of the skin Diseases 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 208000017763 cutaneous neuroendocrine carcinoma Diseases 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 208000037821 progressive disease Diseases 0.000 description 1
- 238000009121 systemic therapy Methods 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021074021A JP2021113220A (ja) | 2015-06-16 | 2021-04-26 | Ｐｄ−ｌ１アンタゴニスト併用療法 |
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562180543P | 2015-06-16 | 2015-06-16 | |
| US62/180,543 | 2015-06-16 | ||
| US201562219995P | 2015-09-17 | 2015-09-17 | |
| US62/219,995 | 2015-09-17 | ||
| US201662286501P | 2016-01-25 | 2016-01-25 | |
| US62/286,501 | 2016-01-25 | ||
| US201662337489P | 2016-05-17 | 2016-05-17 | |
| US62/337,489 | 2016-05-17 | ||
| PCT/US2016/037498 WO2016205277A1 (en) | 2015-06-16 | 2016-06-15 | Pd-l1 antagonist combination treatments |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021074021A Division JP2021113220A (ja) | 2015-06-16 | 2021-04-26 | Ｐｄ−ｌ１アンタゴニスト併用療法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018522850A JP2018522850A (ja) | 2018-08-16 |
| JP2018522850A5 true JP2018522850A5 (cg-RX-API-DMAC7.html) | 2019-07-18 |
| JP6876629B2 JP6876629B2 (ja) | 2021-05-26 |
Family
ID=56236125
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017565142A Active JP6876629B2 (ja) | 2015-06-16 | 2016-06-15 | Ｐｄ−ｌ１アンタゴニスト併用療法 |
| JP2021074021A Pending JP2021113220A (ja) | 2015-06-16 | 2021-04-26 | Ｐｄ−ｌ１アンタゴニスト併用療法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021074021A Pending JP2021113220A (ja) | 2015-06-16 | 2021-04-26 | Ｐｄ−ｌ１アンタゴニスト併用療法 |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US10869924B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3310810A1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP6876629B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR102712880B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN107750166B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2016280003B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2989586A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL256245B (cg-RX-API-DMAC7.html) |
| MX (1) | MX390878B (cg-RX-API-DMAC7.html) |
| MY (1) | MY193229A (cg-RX-API-DMAC7.html) |
| PH (1) | PH12017501857B1 (cg-RX-API-DMAC7.html) |
| RU (1) | RU2766890C2 (cg-RX-API-DMAC7.html) |
| TW (1) | TWI772261B (cg-RX-API-DMAC7.html) |
| UA (1) | UA126892C2 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2016205277A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101764096B1 (ko) * | 2011-11-28 | 2017-08-02 | 메르크 파텐트 게엠베하 | 항-ｐｄ-ｌ1 항체 및 그의 용도 |
| KR101503341B1 (ko) | 2014-03-12 | 2015-03-18 | 국립암센터 | 자가암항원 특이적 cd8+ t 세포의 분리 및 증식방법 |
| BR112017018234A2 (pt) | 2015-02-26 | 2018-04-17 | Merck Patent Gmbh | inibidores de pd-1 / pd-l1 para o tratamento de câncer |
| CN114702586A (zh) | 2015-03-13 | 2022-07-05 | 西托姆克斯治疗公司 | 抗-pdl1抗体、可活化的抗-pdl1抗体、及其使用方法 |
| CN107750166B (zh) | 2015-06-16 | 2022-02-11 | 默克专利股份有限公司 | Pd-l1拮抗剂组合治疗 |
| MA42459A (fr) | 2015-07-16 | 2018-05-23 | Bioxcel Therapeutics Inc | Nouvelle approche pour le traitement du cancer par immunomodulation |
| PT3386541T (pt) | 2015-12-07 | 2020-10-12 | Merck Patent Gmbh | Formulação farmacêutica aquosa compreendendo o anticorpo anti-pd-1 avelumab |
| BR112018014016A2 (pt) * | 2016-01-25 | 2019-02-05 | Pfizer | combinação de um agonista de ox40 e um agonista de anticorpo monoclonal 4-1bb para tratamento de câncer |
| CA3025391A1 (en) * | 2016-05-26 | 2017-11-30 | Merck Patent Gmbh | Pd-1 / pd-l1 inhibitors for cancer treatment |
| US11274154B2 (en) * | 2016-10-06 | 2022-03-15 | Pfizer Inc. | Dosing regimen of avelumab for the treatment of cancer |
| KR102089072B1 (ko) | 2017-01-06 | 2020-03-17 | 주식회사 유틸렉스 | 항-인간 4-1bb 항체 및 그의 용도 |
| ES2953595T3 (es) | 2017-03-01 | 2023-11-14 | Hoffmann La Roche | Procedimientos diagnósticos y terapéuticos para el cáncer |
| UA129583C2 (uk) | 2017-03-06 | 2025-06-11 | Мерк Патент Гмбх | Водний фармацевтичний склад, який містить антитіло проти pd-l1 авелумаб |
| EP3372615A1 (en) | 2017-03-06 | 2018-09-12 | Merck Patent GmbH | Composition comprising avelumab |
| MX2019011657A (es) * | 2017-03-30 | 2019-11-18 | Merck Patent Gmbh | Combinacion de un anticuerpo anti ligando 1 de muerte programada (pd-l1) e inhibidor de proteina cinasa dependiente de acido desoxirribonucleico (dna-pk) para tratamiento de cancer. |
| US11168144B2 (en) | 2017-06-01 | 2021-11-09 | Cytomx Therapeutics, Inc. | Activatable anti-PDL1 antibodies, and methods of use thereof |
| CN117946278A (zh) * | 2017-06-25 | 2024-04-30 | 西雅图免疫公司 | 多特异性抗体及其制备和使用方法 |
| WO2019096194A1 (zh) * | 2017-11-16 | 2019-05-23 | 江苏恒瑞医药股份有限公司 | Pd-1抗体和vegfr抑制剂联合治疗小细胞肺癌的用途 |
| AU2019209435A1 (en) * | 2018-01-22 | 2020-09-17 | Bristol-Myers Squibb Company | Compositions and methods of treating cancer |
| CN111867679A (zh) * | 2018-03-06 | 2020-10-30 | 居里研究所 | 用于癌症联合治疗的setdb1组蛋白甲基转移酶抑制剂 |
| CN117362436A (zh) * | 2018-03-29 | 2024-01-09 | 桂林三金药业股份有限公司 | 抗pd-l1抗体及其用途 |
| WO2019196309A1 (zh) | 2018-04-09 | 2019-10-17 | 上海原能细胞医学技术有限公司 | 抗pd-l1抗体及其用途 |
| CN116585466A (zh) | 2018-05-10 | 2023-08-15 | 瑞泽恩制药公司 | 含有高浓度vegf受体融合蛋白的制剂 |
| WO2020014419A2 (en) * | 2018-07-11 | 2020-01-16 | Momenta Pharmaceuticals Inc | Compositions and methods related to engineered fc-antigen binding domain constructs targeted to pd-l1 |
| AU2019361983A1 (en) * | 2018-10-18 | 2021-05-20 | Genentech, Inc. | Diagnostic and therapeutic methods for sarcomatoid kidney cancer |
| CN114340679A (zh) * | 2018-10-31 | 2022-04-12 | 基因泰克公司 | 用于治疗对pd-1/pd-l1信号传导抑制剂无应答的癌症的方法和药物 |
| WO2020123477A1 (en) * | 2018-12-10 | 2020-06-18 | Bioxcel Therapeutics, Inc. | Combination therapies for treating disease using an innate immunity modifier and an ox40 agonist |
| CN113164599B (zh) * | 2018-12-24 | 2023-08-01 | 正大天晴药业集团股份有限公司 | 抗pd-l1单克隆抗体治疗癌症的用途 |
| CN118267468A (zh) | 2019-01-25 | 2024-07-02 | 正大天晴药业集团股份有限公司 | 治疗肿瘤的联用药物组合物 |
| CA3136453A1 (en) | 2019-04-18 | 2020-10-22 | Qlsf Biotherapeutics Inc. | Humanized anti-pd-l1 antibodies |
| WO2020249018A1 (zh) * | 2019-06-10 | 2020-12-17 | 正大天晴药业集团南京顺欣制药有限公司 | 治疗驱动基因阳性肺癌的联用药物组合物 |
| CN110746493A (zh) * | 2019-09-06 | 2020-02-04 | 中国药科大学 | 一种pd-l1拮抗剂多肽及其应用 |
| CN110760517B (zh) * | 2019-10-09 | 2022-04-29 | 天津大学 | 拮抗pd-1骆驼抗体类似物ap基因及蛋白和应用 |
| TW202202138A (zh) | 2020-03-25 | 2022-01-16 | 美商歐克萊製藥公司 | 含有酪胺酸激酶抑制劑之眼用植入物 |
| US20230227556A1 (en) * | 2020-04-30 | 2023-07-20 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Combination drug for treating kidney cancer |
| WO2022068894A1 (zh) * | 2020-09-30 | 2022-04-07 | 上海齐鲁制药研究中心有限公司 | 同时靶向pd-l1和vegf的双功能分子及其医药用途 |
| WO2022111618A1 (zh) * | 2020-11-26 | 2022-06-02 | 正大天晴药业集团股份有限公司 | 用于治疗肺癌的抗PD-L1抗体和c-Met激酶抑制剂的联用药物组合物 |
| CN120897764A (zh) | 2023-04-11 | 2025-11-04 | 视尔普斯眼科公司 | 包含阿西替尼多晶型物iv的眼部植入物 |
Family Cites Families (112)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1000475A (en) | 1908-12-31 | 1911-08-15 | Rodney Robert Woodson | Coal-mining pick. |
| US1013829A (en) | 1911-04-17 | 1912-01-02 | Narragansett Machine Company | Vaulting-bar. |
| US1032309A (en) | 1911-08-05 | 1912-07-09 | Pembroke N Squires | Headlight-adjuster for motor-vehicles. |
| US1057020A (en) | 1912-03-18 | 1913-03-25 | Robert C Wade | Sectional smoke-burner. |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| ATE139258T1 (de) | 1990-01-12 | 1996-06-15 | Cell Genesys Inc | Erzeugung xenogener antikörper |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| AU8507191A (en) | 1990-08-29 | 1992-03-30 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| AU3178993A (en) | 1991-11-25 | 1993-06-28 | Enzon, Inc. | Multivalent antigen-binding proteins |
| JPH07263576A (ja) | 1994-03-25 | 1995-10-13 | Hitachi Ltd | 半導体集積回路装置およびその製造方法 |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| AU5632296A (en) | 1995-04-27 | 1996-11-18 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| WO1996034096A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| EP2305027B1 (en) | 1996-12-03 | 2014-07-02 | Amgen Fremont Inc. | Transgenic mammals having human Ig loci including plural VH and Vkappa regions and antibodies produced therefrom |
| AU760562B2 (en) | 1997-12-05 | 2003-05-15 | Scripps Research Institute, The | Humanization of murine antibody |
| US7141581B2 (en) | 1999-07-02 | 2006-11-28 | Agouron Pharmaceuticals, Inc. | Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use |
| TWI262914B (en) | 1999-07-02 | 2006-10-01 | Agouron Pharma | Compounds and pharmaceutical compositions for inhibiting protein kinases |
| US7794710B2 (en) | 2001-04-20 | 2010-09-14 | Mayo Foundation For Medical Education And Research | Methods of enhancing T cell responsiveness |
| US7595048B2 (en) | 2002-07-03 | 2009-09-29 | Ono Pharmaceutical Co., Ltd. | Method for treatment of cancer by inhibiting the immunosuppressive signal induced by PD-1 |
| JP4511943B2 (ja) | 2002-12-23 | 2010-07-28 | ワイス エルエルシー | Ｐｄ−１に対する抗体およびその使用 |
| JP4532409B2 (ja) | 2003-01-23 | 2010-08-25 | 小野薬品工業株式会社 | ヒトｐｄ−１に対し特異性を有する物質 |
| CN1832743A (zh) * | 2003-04-03 | 2006-09-13 | 美国辉瑞有限公司 | 包含ag013736的剂型 |
| JP2006522087A (ja) | 2003-04-03 | 2006-09-28 | ファイザー・インク | Ａｇ０１３７３６を含んでなる剤形 |
| AR045563A1 (es) | 2003-09-10 | 2005-11-02 | Warner Lambert Co | Anticuerpos dirigidos a m-csf |
| RU2401277C2 (ru) | 2004-01-07 | 2010-10-10 | Чирон Корпорейшн | Не мышиное анти-m-csf-антитело (варианты), его получение и использование |
| MX2007005273A (es) | 2004-11-02 | 2007-07-19 | Pfizer | Formas polimorficas de 6-[2-(metilcarbamoil)fenilsulfanil]-3- e-[2-(piridin-2-il)etenil]indazol. |
| WO2006048746A2 (en) | 2004-11-02 | 2006-05-11 | Pfizer Inc. | Methods for the removal of heavy metals |
| CN101044138A (zh) | 2004-11-02 | 2007-09-26 | 辉瑞有限公司 | 吲唑化合物的制备方法 |
| CN101052633A (zh) | 2004-11-02 | 2007-10-10 | 辉瑞大药厂 | 制备吲唑化合物的方法 |
| WO2006048744A1 (en) | 2004-11-02 | 2006-05-11 | Pfizer Inc. | Methods of preparing indazole compounds |
| EP3530736A3 (en) | 2005-05-09 | 2019-11-06 | ONO Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics |
| CA2608952A1 (en) | 2005-05-19 | 2006-11-23 | Dwayne Thomas Friesen | Pharmaceutical compostions comprising an amorphous form of a vegf-r inhibitor |
| KR101888321B1 (ko) | 2005-07-01 | 2018-08-13 | 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체 |
| WO2008100562A2 (en) | 2007-02-14 | 2008-08-21 | Medical College Of Georgia Research Institute, Inc. | Indoleamine 2,3-dioxygenase, pd-1/pd-l pathways, and ctla4 pathways in the activation of regulatory t cells |
| ES2634866T5 (es) | 2007-04-05 | 2024-03-04 | Pfizer Prod Inc | Formas cristalinas de 6-[2-(metilcarbamoil)fenilsulfanil]-3-[2-(piridin-2-il)etenil]indazol adecuadas para el tratamiento del crecimiento celular anormal en mamíferos |
| NZ600758A (en) | 2007-06-18 | 2013-09-27 | Merck Sharp & Dohme | Antibodies to human programmed death receptor pd-1 |
| MX2010006466A (es) | 2007-12-14 | 2010-09-28 | Bristol Myers Squibb Co | Moleculas de union al receptor ox40 de humano. |
| EP2262837A4 (en) | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | PD-1 BINDING PROTEINS |
| US20110159023A1 (en) | 2008-08-25 | 2011-06-30 | Solomon Langermann | Pd-1 antagonists and methods for treating infectious disease |
| HUE030807T2 (en) | 2008-09-26 | 2017-05-29 | Dana Farber Cancer Inst Inc | Human anti-PD-1, anti-PD-L1 and anti-PD-L2 antibodies and their applications |
| US8563735B2 (en) * | 2008-12-05 | 2013-10-22 | Abbvie Inc. | Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases |
| TWI605828B (zh) * | 2008-12-09 | 2017-11-21 | 建南德克公司 | 抗ｐｄ-ｌ１抗體及其於增進ｔ細胞功能之用途 |
| EP2393835B1 (en) | 2009-02-09 | 2017-04-05 | Université d'Aix-Marseille | Pd-1 antibodies and pd-l1 antibodies and uses thereof |
| EP2504028A4 (en) | 2009-11-24 | 2014-04-09 | Amplimmune Inc | SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2 |
| WO2011066389A1 (en) | 2009-11-24 | 2011-06-03 | Medimmmune, Limited | Targeted binding agents against b7-h1 |
| CN102892786B (zh) | 2010-03-11 | 2016-03-16 | Ucb医药有限公司 | Pd-1抗体 |
| WO2012012518A2 (en) * | 2010-07-20 | 2012-01-26 | University Of Miami | Inhibition of nonsense mediated decay pathways |
| DK2612151T3 (en) | 2010-08-31 | 2017-10-02 | Genentech Inc | BIOMARKETS AND METHODS OF TREATMENT |
| RU2551963C2 (ru) | 2010-09-09 | 2015-06-10 | Пфайзер Инк. | Молекулы, связывающиеся с 4-1вв |
| TR201905909T4 (tr) * | 2011-04-19 | 2019-05-21 | Pfizer | Kanser tedavisi için anti-4-1bb antikorlarının ve adcc indükleyici antikorların kombinasyonları. |
| WO2012162561A2 (en) | 2011-05-24 | 2012-11-29 | Zyngenia, Inc. | Multivalent and monovalent multispecific complexes and their uses |
| JP6238459B2 (ja) | 2011-08-01 | 2017-11-29 | ジェネンテック， インコーポレイテッド | Ｐｄ−１軸結合アンタゴニストとｍｅｋ阻害剤を使用する癌の治療方法 |
| JP6038920B2 (ja) | 2011-08-23 | 2016-12-07 | ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム | 抗ｏｘ４０抗体およびそれを使用する方法 |
| KR20140069297A (ko) | 2011-09-30 | 2014-06-09 | 화이자 인코포레이티드 | N-메틸-2-[3-((e)-2-피리딘-2-일-비닐)-1h-인다졸-6-일-설파닐]-벤즈아미드의 약학 조성물 |
| JP2014533262A (ja) | 2011-11-11 | 2014-12-11 | ファイザー・インク | 慢性骨髄性白血病を治療するためのｎ−メチル−２−［３−（（ｅ）−２−ピリジン−２−イル−ビニル）−１ｈ−インダゾール−６−イルスルファニル］−ベンズアミド |
| KR101764096B1 (ko) * | 2011-11-28 | 2017-08-02 | 메르크 파텐트 게엠베하 | 항-ｐｄ-ｌ1 항체 및 그의 용도 |
| AU2012369202A1 (en) | 2012-02-06 | 2014-09-25 | Providence Health & Services - Oregon | Cancer treatment and monitoring methods using OX40 agonists |
| SG10201603896RA (en) | 2012-05-04 | 2016-07-28 | Pfizer | Prostate-associated antigens and vaccine-based immunotherapy regimens |
| WO2013173223A1 (en) | 2012-05-15 | 2013-11-21 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting pd-1/pd-l1 signaling |
| SG10201603055WA (en) | 2012-05-31 | 2016-05-30 | Genentech Inc | Methods Of Treating Cancer Using PD-L1 Axis Binding Antagonists And VEGF Antagonists |
| US9682143B2 (en) | 2012-08-14 | 2017-06-20 | Ibc Pharmaceuticals, Inc. | Combination therapy for inducing immune response to disease |
| AR093984A1 (es) | 2012-12-21 | 2015-07-01 | Merck Sharp & Dohme | Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano |
| MY197809A (en) | 2013-03-15 | 2023-07-18 | Genentech Inc | Biomarkers and methods of treating pd-1 and pd-l1 related conditions |
| CN107252485A (zh) | 2013-04-03 | 2017-10-17 | Ibc药品公司 | 用于诱导对疾病的免疫应答的组合疗法 |
| CN105121466A (zh) | 2013-04-12 | 2015-12-02 | 莫佛塞斯公司 | 靶向m-csf的抗体 |
| DE102013008118A1 (de) | 2013-05-11 | 2014-11-13 | Merck Patent Gmbh | Arylchinazoline |
| KR102232153B1 (ko) * | 2013-08-20 | 2021-03-24 | 머크 샤프 앤드 돔 코포레이션 | Pd-1 길항제와 디나시클립의 조합을 사용한 암의 치료 |
| BR112016005303A2 (pt) | 2013-09-11 | 2017-09-12 | Medimmune Ltd | anticorpos anti-b7-h1 para tratamento de tumores |
| AR097584A1 (es) * | 2013-09-12 | 2016-03-23 | Hoffmann La Roche | Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano |
| WO2015061668A1 (en) | 2013-10-25 | 2015-04-30 | Dana-Farber Cancer Institute, Inc. | Anti-pd-l1 monoclonal antibodies and fragments thereof |
| EP4461372A3 (en) | 2013-11-05 | 2025-01-22 | Cognate Bioservices, Inc. | Combinations of checkpoint inhibitors and therapeutics to treat cancer |
| US9457019B2 (en) | 2013-11-07 | 2016-10-04 | Deciphera Pharmaceuticals, Llc | Methods for inhibiting tie-2 kinase useful in the treatment of cancer |
| AU2013404949B2 (en) | 2013-11-07 | 2018-10-18 | Deciphera Pharmaceuticals, Llc | Methods for inhibiting TIE2 kinase useful in the treatment of cancer |
| WO2015088847A1 (en) | 2013-12-11 | 2015-06-18 | Glaxosmithkline Llc | Treating cancer with a combination of a pd-1 antagonist and a vegfr inhibitor |
| JP2017501167A (ja) | 2013-12-17 | 2017-01-12 | ジェネンテック， インコーポレイテッド | Ｏｘ４０結合アゴニスト及びｐｄ−１軸結合アンタゴニストを含む併用療法 |
| SG11201604875PA (en) | 2013-12-17 | 2016-07-28 | Genentech Inc | Methods of treating cancer using pd-1 axis binding antagonists and an anti-cd20 antibody |
| US9045545B1 (en) | 2014-07-15 | 2015-06-02 | Kymab Limited | Precision medicine by targeting PD-L1 variants for treatment of cancer |
| CN105934253A (zh) | 2013-12-17 | 2016-09-07 | 豪夫迈·罗氏有限公司 | 使用pd-1轴结合拮抗剂和抗her2抗体治疗her2阳性癌症的方法 |
| JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
| TR201901507T4 (tr) | 2014-02-04 | 2019-02-21 | Merck Sharp & Dohme | Kanseri tedavi etmeye yönelik bir pd-1 antagonsitinin ve bir vegfr inhibitörünün kombinasyonu. |
| EP3107538B1 (en) | 2014-02-18 | 2020-05-27 | Health Research, Inc. | Combination therapy for hepatocellular carcinoma |
| WO2015134605A1 (en) | 2014-03-05 | 2015-09-11 | Bristol-Myers Squibb Company | Treatment of renal cancer using a combination of an anti-pd-1 antibody and another anti-cancer agent |
| CN106714839A (zh) | 2014-05-15 | 2017-05-24 | 百时美施贵宝公司 | 使用抗pd‑1抗体和另一种抗癌剂的组合治疗肺癌 |
| US20160009805A1 (en) | 2014-07-11 | 2016-01-14 | Genentech, Inc. | Anti-pd-l1 antibodies and diagnostic uses thereof |
| WO2016014148A1 (en) | 2014-07-23 | 2016-01-28 | Mayo Foundation For Medical Education And Research | Targeting dna-pkcs and b7-h1 to treat cancer |
| WO2016022813A1 (en) | 2014-08-07 | 2016-02-11 | Aerpio Therapeutics, Inc. | Combination of immunotherapies with activators of tie-2 |
| EP3185866A1 (en) | 2014-08-25 | 2017-07-05 | Pfizer Inc. | Combination of a pd-1 antagonist and an alk inhibitor for treating cancer |
| CN112587672A (zh) * | 2014-09-01 | 2021-04-02 | 博笛生物科技有限公司 | 用于治疗肿瘤的抗-pd-l1结合物 |
| CN107206071A (zh) | 2014-09-13 | 2017-09-26 | 诺华股份有限公司 | Alk抑制剂的联合疗法 |
| EP3662903A3 (en) | 2014-10-03 | 2020-10-14 | Novartis AG | Combination therapies |
| EA201790834A1 (ru) | 2014-10-14 | 2018-01-31 | Новартис Аг | Молекулы антител к pd-l1 и их применение |
| WO2016059602A2 (en) | 2014-10-16 | 2016-04-21 | Glaxo Group Limited | Methods of treating cancer and related compositions |
| HRP20210440T1 (hr) | 2014-10-29 | 2021-04-30 | Five Prime Therapeutics, Inc. | Kombinirana terapija za rak |
| SG10201807625PA (en) | 2014-11-17 | 2018-10-30 | Genentech Inc | Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists |
| AU2015355137A1 (en) | 2014-12-02 | 2017-06-08 | Celgene Corporation | Combination therapies |
| GB201421647D0 (en) | 2014-12-05 | 2015-01-21 | Amcure Gmbh And Ruprecht-Karls-Universitat And Karlsruher Institut F�R Technologie | CD44v6-derived cyclic peptides for treating cancers and angiogenesis related diseases |
| TWI595006B (zh) | 2014-12-09 | 2017-08-11 | 禮納特神經系統科學公司 | 抗ｐｄ－１抗體類和使用彼等之方法 |
| WO2016100882A1 (en) | 2014-12-19 | 2016-06-23 | Novartis Ag | Combination therapies |
| BR112017018234A2 (pt) | 2015-02-26 | 2018-04-17 | Merck Patent Gmbh | inibidores de pd-1 / pd-l1 para o tratamento de câncer |
| CN107750166B (zh) | 2015-06-16 | 2022-02-11 | 默克专利股份有限公司 | Pd-l1拮抗剂组合治疗 |
| CA3000386A1 (en) | 2015-09-30 | 2017-04-06 | Merck Patent Gmbh | Combination of a pd-1 axis binding antagonist and an alk inhibitor for treating alk-negative cancer |
| TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療 |
| CA3025391A1 (en) | 2016-05-26 | 2017-11-30 | Merck Patent Gmbh | Pd-1 / pd-l1 inhibitors for cancer treatment |
| US11274154B2 (en) | 2016-10-06 | 2022-03-15 | Pfizer Inc. | Dosing regimen of avelumab for the treatment of cancer |
| MX2019011657A (es) | 2017-03-30 | 2019-11-18 | Merck Patent Gmbh | Combinacion de un anticuerpo anti ligando 1 de muerte programada (pd-l1) e inhibidor de proteina cinasa dependiente de acido desoxirribonucleico (dna-pk) para tratamiento de cancer. |
-
2016
- 2016-06-15 CN CN201680035168.3A patent/CN107750166B/zh active Active
- 2016-06-15 CA CA2989586A patent/CA2989586A1/en active Pending
- 2016-06-15 IL IL256245A patent/IL256245B/en unknown
- 2016-06-15 US US15/736,615 patent/US10869924B2/en active Active
- 2016-06-15 PH PH1/2017/501857A patent/PH12017501857B1/en unknown
- 2016-06-15 MX MX2017016324A patent/MX390878B/es unknown
- 2016-06-15 KR KR1020187001350A patent/KR102712880B1/ko active Active
- 2016-06-15 AU AU2016280003A patent/AU2016280003B2/en active Active
- 2016-06-15 RU RU2018101314A patent/RU2766890C2/ru active
- 2016-06-15 MY MYPI2017704745A patent/MY193229A/en unknown
- 2016-06-15 UA UAA201800418A patent/UA126892C2/uk unknown
- 2016-06-15 WO PCT/US2016/037498 patent/WO2016205277A1/en not_active Ceased
- 2016-06-15 EP EP16732440.9A patent/EP3310810A1/en active Pending
- 2016-06-15 JP JP2017565142A patent/JP6876629B2/ja active Active
- 2016-06-16 TW TW105118967A patent/TWI772261B/zh active
-
2020
- 2020-11-19 US US16/952,620 patent/US20210069326A1/en not_active Abandoned
-
2021
- 2021-04-26 JP JP2021074021A patent/JP2021113220A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018522850A5 (cg-RX-API-DMAC7.html) | ||
| RU2018101314A (ru) | Комбинированные способы лечения антагонистами pd-l1 | |
| Guan et al. | Adverse events of monoclonal antibodies used for cancer therapy | |
| US11220548B2 (en) | Treatment of C1013G/CXCR4-associated Waldenstrom's macroglobulinemia with an anti-CXCR4 antibody | |
| US20150231238A1 (en) | Overcoming resistance to erbb pathway inhibitors | |
| JP2019506403A5 (cg-RX-API-DMAC7.html) | ||
| JP7491220B2 (ja) | 免疫チェックポイント阻害薬およびｆｏｌｆｉｒｉｎｏｘ療法との併用によるがん治療 | |
| JP2025185043A (ja) | 癌を治療するための免疫調節剤と組み合わせた低酸素活性化型プロドラッグの投与 | |
| Francis et al. | Pan-HER inhibitor augments radiation response in human lung and head and neck cancer models | |
| JP2019508433A5 (cg-RX-API-DMAC7.html) | ||
| Abeykoon et al. | New developments in the management of Waldenström macroglobulinemia | |
| Ito et al. | Does lapatinib, a small-molecule tyrosine kinase inhibitor, constitute a breakthrough in the treatment of breast cancer? | |
| EP3463453A1 (en) | Combination of pembrolizumab and abemaciclib for the treatment of cancer | |
| US20210267972A1 (en) | Administration of sumo-activating enzyme inhibitor and anti-cd20 antibodies | |
| JP2022502399A (ja) | がんの治療のためのｐｄ−１アンタゴニスト、ａｔｒインヒビター、および白金製剤の組合せ | |
| Hoag et al. | Association of cetuximab with adverse pulmonary events in cancer patients: a comprehensive review | |
| JP2020507596A5 (cg-RX-API-DMAC7.html) | ||
| Savino et al. | Evaluation of intraorbital injection of rituximab for treatment of primary ocular adnexal lymphoma: a pilot study | |
| Kastritis et al. | Proteasome inhibitors in Waldenström macroglobulinemia | |
| CN111973747A (zh) | 用于联合治疗卵巢癌的喹啉衍生物 | |
| WO2017176565A1 (en) | Combinations of an anti-b7-h1 antibody and a cxcr4 peptide antagonist for treating a solid tumor | |
| Michel et al. | T-DM1 as a new treatment option for patients with metastatic HER2-positive breast cancer in clinical practice | |
| Yonemori et al. | Phase 1 study of olaratumab plus doxorubicin in Japanese patients with advanced soft‐tissue sarcoma | |
| Turkington et al. | A phase I trial of bortezomib in combination with epirubicin, carboplatin and capecitabine (ECarboX) in advanced oesophagogastric adenocarcinoma | |
| Saito et al. | Safety evaluation of initial CT-P6 administration for 30 min during the switch from reference trastuzumab in maintenance infusion: a multicenter observational study |